## RVTY: Revvity, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -3.1% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.4% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($90.00)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Revvity (RVTY): Valuation Check After Launch of Signals Xynthetica AI Models-as-a-Service Platform**
- Source: Simply Wall Street | 20251219T190847 | Somewhat-Bullish | Relevance: 100%
- Revvity (RVTY) has launched its Signals Xynthetica AI Models-as-a-Service platform, integrating AI-driven molecular and materials design. Despite this innovation, the stock has seen a 30-day return of 4.35% and a -14.24% annual return. The company is currently trading at an estimated 25% discount to its intrinsic value and 19% below analyst targets, prompting questions about a potential buying opportunity.

**2. Revvity Advances AI-Driven Scientific Discovery With Signals Xynthetica**
- Source: TradingView — Track All Markets | 20251219T140846 | Bullish | Relevance: 100%
- Revvity, Inc. introduced Signals Xynthetica, an AI-augmented design platform for molecular and materials discovery, delivered as a Models-as-a-Service solution within the Revvity Signals ecosystem. This platform unifies de novo generation, property prediction, and multi-objective optimization to accelerate scientific R&D by integrating computational models with experimental workflows. Early access is expected in the first half of 2026, positioning Revvity as a key player in data-driven innovation across pharmaceuticals, biotechnology, and materials science.

**3. Raymond James reiterates Outperform rating on Revvity stock after site visit**
- Source: Investing.com UK | 20251219T100855 | Bullish | Relevance: 100%
- Raymond James has reiterated an Outperform rating and a $115.00 price target for Revvity Inc. (NYSE:RVTY) following a site visit to the company's facility near Denver. The firm noted a greater appreciation for Revvity's under-discussed non-BioLegend reagents business and reinforced comfort with its long-term fundamentals, despite acknowledging near-term challenges. This aligns with broader analyst sentiment, although some recent reports from BofA Securities and Goldman Sachs have offered more cautious outlooks.

**4. Raymond James reiterates Outperform rating on Revvity stock after site visit**
- Source: Investing.com | 20251219T100843 | Bullish | Relevance: 100%
- Raymond James has reiterated an Outperform rating and a $115.00 price target for Revvity Inc (NYSE:RVTY) following a site visit to the company's Denver facility. The firm gained a greater appreciation for Revvity’s non-BioLegend reagents business, approaching $300 million, and reaffirmed comfort with the company's long-term fundamentals despite near-term challenges. This reinforces the broader analyst sentiment that Revvity is trading slightly below its Fair Value.

**5. Revvity to Present at J.P. Morgan Healthcare Conference**
- Source: Business Wire | 20251218T130831 | Somewhat-Bullish | Relevance: 100%
- Revvity, Inc. (NYSE: RVTY) announced it will present at the 44th annual J.P. Morgan Healthcare Conference on January 13, 2026, at 9:45 a.m. PT. Prahlad Singh, President and CEO, will provide an update on the Company's strategic priorities. A live audio webcast will be available on the Events section of Revvity’s website, with a replay accessible for at least 30 days post-event.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Barclays | $115 | $105 | +10% |
| 2025-12-15 | Wells Fargo | $107 | $102 | +5% |
| 2025-12-09 | Goldman Sachs | $105 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Barclays | main | Overweight |
| 2025-12-15 | Wells Fargo | main | Equal-Weight |
| 2025-12-09 | Goldman Sachs | init | Neutral |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 72.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- T. Rowe Price Invest: 19.9% (-0.6%)
- Vanguard Group Inc: 11.9% (-4.0%)
- Blackrock Inc.: 8.2% (+4.4%)
- Edgepoint Investment: 7.6% (+26.3%)
- Price (T.Rowe) Assoc: 7.2% (+2.4%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-2.4% 5d) with bearish MACD, trend may be turning.
2. Elevated short interest (9.1%): bears positioning against stock.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.66 indicates undervaluation relative to growth. Forward P/E 18.1x stretched relative to 8% growth. Analyst sentiment positive (2 raises, avg +7%). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $11.2B |
| Beta | 1.06 |
| 52W Range | $81.36 - $128.29 |
| Short Interest | 9.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.66 |
| Forward P/E | 18.1 |
| Current P/E | 19.6 |
| YoY Growth | 7.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -0.7% to -3.1% (-2.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.1pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.01x) but short-term weakness (below SMA20). MACD histogram bearish (-0.99), momentum weakening. RSI neutral at 45. OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -3.06% (CS: 13) | Weak |
| RSI_14 | 44.6 | Neutral |
| MACD Histogram | -0.99 | Bearish |
| vs SMA20 | 0.954x | Below |
| vs SMA50 | 0.998x | Below |
| vs SMA200 | 1.013x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $96.20
- **Stop Loss:** $90.00 (6.4% risk)
- **Target:** $102.40 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 193
- **Position Value:** $18,566.60
- **Portfolio %:** 18.57%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-01-26 (Est: $1.55)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.14 | $1.18 | +3.6% |
| 2025Q2 | $1.14 | $1.18 | +3.4% |
| 2025Q1 | $0.95 | $1.01 | +6.4% |
| 2024Q4 | $1.38 | $1.42 | +3.1% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*